PL2170864T3 - Agoniści receptora gpr119 sprężonego z białkiem g - pirydon - Google Patents

Agoniści receptora gpr119 sprężonego z białkiem g - pirydon

Info

Publication number: PL2170864T3
Authority: PL; Poland
Prior art keywords: gpr119; pyridone; protein; receptor agonists; coupled receptor
Prior art date: 2007-07-17

Application number

PL08781867T

Other languages

English (en)

Inventor

Dean A Wacker

Karen A Rossi

Ying Wang

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-17

Filing date

2008-07-16

Publication date

2012-02-29

2008-07-16 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2012-02-29 Publication of PL2170864T3 publication Critical patent/PL2170864T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Psychiatry (AREA)
Virology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)

PL08781867T 2007-07-17 2008-07-16 Agoniści receptora gpr119 sprężonego z białkiem g - pirydon PL2170864T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US95016207P	2007-07-17	2007-07-17
PCT/US2008/070101 WO2009012275A1 (en)	2007-07-17	2008-07-16	Pyridone gpr119 g protein-coupled receptor agonists
EP08781867A EP2170864B1 (en)	2007-07-17	2008-07-16	Pyridone gpr119 g protein-coupled receptor agonists

Publications (1)

Publication Number	Publication Date
PL2170864T3 true PL2170864T3 (pl)	2012-02-29

Family

ID=39864683

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL08781868T PL2173737T3 (pl)	2007-07-17	2008-07-16	Sposób modulowania receptora GPR119 sprzężonego z białkiem G i wybrane związki
PL08781867T PL2170864T3 (pl)	2007-07-17	2008-07-16	Agoniści receptora gpr119 sprężonego z białkiem g - pirydon

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL08781868T PL2173737T3 (pl)	2007-07-17	2008-07-16	Sposób modulowania receptora GPR119 sprzężonego z białkiem G i wybrane związki

Country Status (27)

Country	Link
US (6)	US7928230B2 (pl)
EP (2)	EP2173737B1 (pl)
JP (3)	JP5301539B2 (pl)
KR (2)	KR20100045471A (pl)
CN (3)	CN103550218A (pl)
AR (2)	AR067568A1 (pl)
AT (2)	ATE540945T1 (pl)
AU (2)	AU2008276055B2 (pl)
BR (2)	BRPI0814428A2 (pl)
CA (2)	CA2693439A1 (pl)
CL (2)	CL2008002111A1 (pl)
CO (1)	CO6160315A2 (pl)
CY (2)	CY1112151T1 (pl)
DK (2)	DK2170864T3 (pl)
EA (2)	EA018709B1 (pl)
ES (2)	ES2378914T3 (pl)
HK (2)	HK1136298A1 (pl)
HR (2)	HRP20110806T1 (pl)
IL (1)	IL228120A0 (pl)
NZ (2)	NZ582661A (pl)
PE (2)	PE20090888A1 (pl)
PL (2)	PL2173737T3 (pl)
PT (2)	PT2173737E (pl)
SI (2)	SI2170864T1 (pl)
TW (2)	TW200904440A (pl)
WO (2)	WO2009012277A1 (pl)
ZA (2)	ZA201000151B (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006059778A1 (ja) *	2004-12-01	2006-06-08	Banyu Pharmaceutical Co., Ltd.	置換ピリドン誘導体
US7910583B2 (en)	2007-05-04	2011-03-22	Bristol-Myers Squibb Company	[6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
EA018709B1 (ru) *	2007-07-17	2013-10-30	Бристол-Маерс Сквибб Компани	Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
EP2146210A1 (en)	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US8304413B2 (en)	2008-06-03	2012-11-06	Intermune, Inc.	Compounds and methods for treating inflammatory and fibrotic disorders
TW201006821A (en) *	2008-07-16	2010-02-16	Bristol Myers Squibb Co	Pyridone and pyridazone analogues as GPR119 modulators
CA2730593A1 (en) *	2008-07-16	2010-01-21	Schering Corporation	Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2010009208A1 (en) *	2008-07-16	2010-01-21	Schering Corporation	Bicyclic heterocycle derivatives and methods of use thereof
GB0904287D0 (en)	2009-03-12	2009-04-22	Prosidion Ltd	Compounds for the treatment of metabolic disorders
CA2754523A1 (en) *	2009-03-20	2010-09-23	Pfizer Inc.	3-oxa-7-azabicyclo[3.3.1]nonanes
TW201113269A (en)	2009-06-24	2011-04-16	Boehringer Ingelheim Int	New compounds, pharmaceutical composition and methods relating thereto
WO2010149684A1 (en)	2009-06-24	2010-12-29	Boehringer Ingelheim International Gmbh	New compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130109703A1 (en)	2010-03-18	2013-05-02	Boehringer Ingelheim International Gmbh	Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
MX2012011460A (es)	2010-04-08	2012-11-23	Squibb Bristol Myers Co	Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
WO2011140161A1 (en)	2010-05-06	2011-11-10	Bristol-Myers Squibb Company	Benzofuranyl analogues as gpr119 modulators
MX2012012902A (es)	2010-05-06	2012-12-17	Bristol Myers Squibb Co	Analogos heteroarilo biciclicos como moduladores de receptor acoplado a la proteina g gpr119.
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
PH12013500671A1 (en)	2010-10-08	2018-04-11	Cadila Healthcare Ltd	Novel gpr 119 agonists
CN103391718A (zh)	2010-12-06	2013-11-13	汇合生命科学股份有限公司	取代的吡啶酮-吡啶基化合物
US9359300B2 (en)	2010-12-06	2016-06-07	Confluence Life Sciences, Inc.	Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
EP2686312B1 (en) *	2011-03-14	2016-08-31	Boehringer Ingelheim International GmbH	N-cyclopropyl-n-piperidinylbenzamides as gpr119 modulators
CA2836487A1 (en)	2011-06-09	2012-12-13	Rhizen Pharmaceuticals Sa	Novel compounds as modulators of gpr-119
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013173198A1 (en)	2012-05-16	2013-11-21	Bristol-Myers Squibb Company	Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
JP2015522080A (ja)	2012-07-11	2015-08-03	エルセリクスセラピューティクスインコーポレイテッド	スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
AR092742A1 (es) *	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
CN104768944B (zh) *	2012-11-13	2017-03-29	日产化学工业株式会社	2‑吡啶酮化合物
CN102993088A (zh) *	2012-12-31	2013-03-27	东华大学	一种4-羟基-2-吡啶酮的制备方法
TWI621618B (zh)	2013-03-13	2018-04-21	比利時商健生藥品公司	經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh)	2013-03-13	2014-12-01	Janssen Pharmaceutica Nv	經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TW201444821A (zh)	2013-03-13	2014-12-01	Janssen Pharmaceutica Nv	經取代之哌啶化合物及其作為食慾素受體調節劑之用途
JP6699909B2 (ja)	2013-06-07	2020-05-27	アクラリスセラピューティクス，インコーポレイテッド	メチル／フルオロ−ピリジニル−メトキシ置換ピリジノン−ピリジニル化合物及びフルオロ−ピリミジニル−メトキシ置換ピリジノン−ピリジニル化合物
CN105473558B (zh)	2013-06-20	2019-04-19	拜耳作物科学股份公司	作为杀螨剂和杀昆虫剂的芳基硫化物衍生物和芳基硫氧化物衍生物
CN105722830B (zh)	2013-06-20	2019-06-04	拜耳作物科学股份公司	作为杀螨剂和杀昆虫剂的芳基硫醚衍生物和芳基亚砜衍生物
BR112016000241B1 (pt)	2013-07-08	2021-06-22	Bayer Cropscience Aktiengesellschaft	Compostos pesticidas derivados de sulfeto de arila e sulfóxido de arila, formulação, seus usos, método para controle de pragas e método de proteção de semente ou planta
KR102373700B1 (ko)	2014-04-02	2022-03-11	인터뮨, 인크.	항섬유성 피리디논
EP2929883A1 (en)	2014-04-08	2015-10-14	Institut Pasteur	Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
CN107108566B (zh)	2014-09-11	2020-11-24	詹森药业有限公司	取代的2-氮杂双环化合物以及它们作为食欲素受体调节剂的用途
US10399948B2 (en)	2015-02-10	2019-09-03	Vanderbilt University	Negative allosteric modulators of metabotropic glutamate receptor 3
JP6578116B2 (ja) *	2015-03-25	2019-09-18	公益財団法人相模中央化学研究所	一置換（フルオロアルキル）エチレン類及びその製造方法
US10865194B2 (en)	2017-11-03	2020-12-15	Fondazione Istituto Italiano Di Tecnologia	Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
EP4110788A4 (en)	2020-02-28	2024-08-28	Kallyope, Inc.	Gpr40 agonists
MX2022011755A (es)	2020-03-27	2022-11-16	Aclaris Therapeutics Inc	Proceso, composiciones y formas cristalinas de compuestos de piridinona-piridinilo sustituidos.
JP2023526625A (ja)	2020-05-19	2023-06-22	キャリーオペ，インク．	Ａｍｐｋアクチベーター
CA3183575A1 (en)	2020-06-26	2021-12-30	Iyassu Sebhat	Ampk activators
WO2022081573A1 (en) *	2020-10-12	2022-04-21	University Of Tennessee Research Foundation	Transient receptor potential canonical 3 inhibitors and methods of use thereof
CN115504927A (zh) *	2022-08-15	2022-12-23	广西中医药大学	4-甲基-2-对甲苯基-6-羰基吡啶-3-甲酸及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3826643A (en) *	1967-08-07	1974-07-30	American Cyanamid Co	Method of controlling undesirable plant species using 3-nitropyridines
US5776983A (en) *	1993-12-21	1998-07-07	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
US5488064A (en) *	1994-05-02	1996-01-30	Bristol-Myers Squibb Company	Benzo 1,3 dioxole derivatives
US5612359A (en) *	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
US5491134A (en) *	1994-09-16	1996-02-13	Bristol-Myers Squibb Company	Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) *	1994-12-02	1996-07-30	Bristol-Myers Squibb Company	Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en)	1995-05-31	1997-04-15	Warner-Lambert Company	Isothiazolones
AU6966696A (en)	1995-10-05	1997-04-28	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
US5770615A (en) *	1996-04-04	1998-06-23	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
US6566384B1 (en) *	1996-08-07	2003-05-20	Darwin Discovery Ltd.	Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW536540B (en) *	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
UA57811C2 (uk)	1997-11-21	2003-07-15	Пфайзер Продактс Інк.	Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
BR9911621A (pt)	1998-07-06	2001-10-16	Bristol Myers Squibb Co	Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
CA2348740A1 (en)	1998-12-23	2000-07-06	Ruth R. Wexler	Thrombin or factor xa inhibitors
WO2002002519A2 (en)	2000-06-29	2002-01-10	Bristol-Myers Squibb Pharma Company	THROMBIN OR FACTOR Xa INHIBITORS
US20030180813A1 (en)	2000-12-01	2003-09-25	Takahide Ohishi	Method of screening remedy for diabetes
US7482366B2 (en) *	2001-12-21	2009-01-27	X-Ceptor Therapeutics, Inc.	Modulators of LXR
AU2002351412B2 (en) *	2001-12-21	2010-05-20	Exelixis Patent Company Llc	Modulators of LXR
SI1490064T1 (sl) *	2002-02-14	2010-01-29	Pharmacia Corp	Substituirani piridinoni kot modulatorji p38 MAP kinaze
ES2295816T3 (es)	2003-01-14	2008-04-16	Arena Pharmaceuticals, Inc.	Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
CN1751038A (zh)	2003-02-24	2006-03-22	艾尼纳制药公司	作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗
SE0301010D0 (sv)	2003-04-07	2003-04-07	Astrazeneca Ab	Novel compounds
US7003597B2 (en) *	2003-07-09	2006-02-21	International Business Machines Corporation	Dynamic reallocation of data stored in buffers based on packet size
CN100509798C (zh) *	2003-07-11	2009-07-08	艾尼纳制药公司	作为新陈代谢调节剂的三取代芳基和杂芳基衍生物以及预防和治疗与其相关之病症
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
JP4920410B2 (ja) *	2003-07-14	2012-04-18	アリーナファーマシューティカルズ，インコーポレイテッド	代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療
US20070088163A1 (en)	2003-09-12	2007-04-19	Kemia, Inc.	Modulators of calcitonin and amylin activity
JPWO2005085200A1 (ja) *	2004-03-05	2008-01-17	萬有製薬株式会社	ピリドン誘導体
WO2005089786A2 (en)	2004-03-17	2005-09-29	7Tm Pharma A/S	Y4 selective receptor agonists for therapeutic interventions
DE602005015962D1 (de) *	2004-05-03	2009-09-24	Hoffmann La Roche	Indolylderivate als liver-x-rezeptormodulatoren
CN1997640A (zh)	2004-06-04	2007-07-11	艾尼纳制药公司	作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗
US8193359B2 (en)	2004-12-24	2012-06-05	Prosidion Limited	G-protein coupled receptor agonists
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
JP5349960B2 (ja) *	2005-06-23	2013-11-20	エモリーユニバーシティー	腫瘍画像化のためのアミノ酸類似体の立体選択的合成
US20090221644A1 (en)	2005-06-30	2009-09-03	Stuart Edward Bradley	Gpcr Agonists
US20090325924A1 (en) *	2005-06-30	2009-12-31	Stuart Edward	GPCR Agonists
US8093257B2 (en)	2007-05-04	2012-01-10	Bristol-Myers Squibb Company	[6,5]-bicyclic GPR119 G protein-coupled receptor agonists
US7910583B2 (en)	2007-05-04	2011-03-22	Bristol-Myers Squibb Company	[6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
EA018709B1 (ru)	2007-07-17	2013-10-30	Бристол-Маерс Сквибб Компани	Пиридоновые агонисты сопряженного с g-белком рецептора gpr119

2008
- 2008-07-16 EA EA201000210A patent/EA018709B1/ru not_active IP Right Cessation
- 2008-07-16 US US12/173,864 patent/US7928230B2/en active Active
- 2008-07-16 BR BRPI0814428-1A2A patent/BRPI0814428A2/pt not_active IP Right Cessation
- 2008-07-16 TW TW097127046A patent/TW200904440A/zh unknown
- 2008-07-16 AT AT08781868T patent/ATE540945T1/de active
- 2008-07-16 WO PCT/US2008/070103 patent/WO2009012277A1/en active Application Filing
- 2008-07-16 CA CA2693439A patent/CA2693439A1/en not_active Abandoned
- 2008-07-16 PE PE2008001196A patent/PE20090888A1/es not_active Application Discontinuation
- 2008-07-16 SI SI200830464T patent/SI2170864T1/sl unknown
- 2008-07-16 TW TW097127045A patent/TW200904439A/zh unknown
- 2008-07-16 ES ES08781868T patent/ES2378914T3/es active Active
- 2008-07-16 DK DK08781867.0T patent/DK2170864T3/da active
- 2008-07-16 JP JP2010517123A patent/JP5301539B2/ja not_active Expired - Fee Related
- 2008-07-16 AU AU2008276055A patent/AU2008276055B2/en not_active Ceased
- 2008-07-16 KR KR1020107003332A patent/KR20100045471A/ko not_active Withdrawn
- 2008-07-16 AR ARP080103060A patent/AR067568A1/es unknown
- 2008-07-16 US US12/173,856 patent/US8003796B2/en active Active
- 2008-07-16 JP JP2010517122A patent/JP5318867B2/ja not_active Expired - Fee Related
- 2008-07-16 PL PL08781868T patent/PL2173737T3/pl unknown
- 2008-07-16 PT PT08781868T patent/PT2173737E/pt unknown
- 2008-07-16 CN CN201310495045.6A patent/CN103550218A/zh active Pending
- 2008-07-16 PL PL08781867T patent/PL2170864T3/pl unknown
- 2008-07-16 NZ NZ582661A patent/NZ582661A/en not_active IP Right Cessation
- 2008-07-16 AT AT08781867T patent/ATE524460T1/de active
- 2008-07-16 AU AU2008276057A patent/AU2008276057B2/en not_active Ceased
- 2008-07-16 EA EA201000211A patent/EA016595B1/ru not_active IP Right Cessation
- 2008-07-16 DK DK08781868.8T patent/DK2173737T3/da active
- 2008-07-16 KR KR1020107003333A patent/KR20100051814A/ko not_active Withdrawn
- 2008-07-16 EP EP08781868A patent/EP2173737B1/en not_active Not-in-force
- 2008-07-16 CN CN200880108168A patent/CN101801957A/zh active Pending
- 2008-07-16 CA CA2693444A patent/CA2693444A1/en not_active Abandoned
- 2008-07-16 EP EP08781867A patent/EP2170864B1/en not_active Not-in-force
- 2008-07-16 PE PE2008001197A patent/PE20090449A1/es not_active Application Discontinuation
- 2008-07-16 CN CN2008801081672A patent/CN101801956B/zh not_active Expired - Fee Related
- 2008-07-16 PT PT08781867T patent/PT2170864E/pt unknown
- 2008-07-16 AR ARP080103061A patent/AR067569A1/es not_active Application Discontinuation
- 2008-07-16 NZ NZ582664A patent/NZ582664A/en not_active IP Right Cessation
- 2008-07-16 SI SI200830592T patent/SI2173737T1/sl unknown
- 2008-07-16 WO PCT/US2008/070101 patent/WO2009012275A1/en active Application Filing
- 2008-07-16 BR BRPI0815097A patent/BRPI0815097A2/pt not_active IP Right Cessation
- 2008-07-16 ES ES08781867T patent/ES2371515T3/es active Active
- 2008-07-17 CL CL200802111A patent/CL2008002111A1/es unknown
- 2008-07-17 CL CL200802110A patent/CL2008002110A1/es unknown
2010
- 2010-01-08 ZA ZA2010/00151A patent/ZA201000151B/en unknown
- 2010-01-15 ZA ZA2010/00326A patent/ZA201000326B/en unknown
- 2010-01-15 CO CO10003756A patent/CO6160315A2/es unknown
- 2010-04-15 HK HK10103702.1A patent/HK1136298A1/xx not_active IP Right Cessation
- 2010-10-05 HK HK10109487.9A patent/HK1143136A1/xx not_active IP Right Cessation
2011
- 2011-03-07 US US13/041,564 patent/US8178561B2/en active Active
- 2011-06-14 US US13/159,497 patent/US8232404B2/en active Active
- 2011-11-02 HR HR20110806T patent/HRP20110806T1/hr unknown
- 2011-12-14 CY CY20111101241T patent/CY1112151T1/el unknown
2012
- 2012-03-07 HR HR20120221T patent/HRP20120221T1/hr unknown
- 2012-04-09 CY CY20121100343T patent/CY1112751T1/el unknown
- 2012-04-24 US US13/454,789 patent/US20120232048A1/en not_active Abandoned
- 2012-06-12 US US13/494,489 patent/US8513424B2/en active Active
2013
- 2013-07-10 JP JP2013144778A patent/JP2013237680A/ja not_active Withdrawn
- 2013-08-26 IL IL228120A patent/IL228120A0/en unknown

Also Published As

Publication number	Publication date
CL2008002110A1 (es)	2008-10-24
ZA201000326B (en)	2011-03-30
US20110190327A1 (en)	2011-08-04
CA2693444A1 (en)	2009-01-22
CN101801957A (zh)	2010-08-11
AR067568A1 (es)	2009-10-14
US20090023702A1 (en)	2009-01-22
CO6160315A2 (es)	2010-05-20
KR20100045471A (ko)	2010-05-03
PE20090888A1 (es)	2009-07-15
CL2008002111A1 (es)	2008-10-24
WO2009012275A1 (en)	2009-01-22
ES2378914T3 (es)	2012-04-19
EP2170864A1 (en)	2010-04-07
EA201000210A1 (ru)	2010-06-30
NZ582661A (en)	2012-03-30
JP2013237680A (ja)	2013-11-28
CN101801956A (zh)	2010-08-11
ES2371515T3 (es)	2012-01-04
SI2173737T1 (sl)	2012-05-31
US8513424B2 (en)	2013-08-20
AR067569A1 (es)	2009-10-14
TW200904440A (en)	2009-02-01
AU2008276057A1 (en)	2009-01-22
PT2173737E (pt)	2012-03-19
EP2173737A1 (en)	2010-04-14
AU2008276055A1 (en)	2009-01-22
US8003796B2 (en)	2011-08-23
JP5301539B2 (ja)	2013-09-25
US20120232048A1 (en)	2012-09-13
DK2173737T3 (da)	2012-05-07
US20110245227A1 (en)	2011-10-06
PT2170864E (pt)	2011-11-25
KR20100051814A (ko)	2010-05-18
HK1143136A1 (en)	2010-12-24
EA201000211A1 (ru)	2010-06-30
CY1112151T1 (el)	2015-12-09
SI2170864T1 (sl)	2012-04-30
PL2173737T3 (pl)	2012-06-29
CA2693439A1 (en)	2009-01-22
IL228120A0 (en)	2013-09-30
EP2173737B1 (en)	2012-01-11
ATE524460T1 (de)	2011-09-15
CY1112751T1 (el)	2016-02-10
US8232404B2 (en)	2012-07-31
CN103550218A (zh)	2014-02-05
US20120258959A1 (en)	2012-10-11
US20090042919A1 (en)	2009-02-12
JP5318867B2 (ja)	2013-10-16
EA016595B1 (ru)	2012-06-29
HRP20120221T1 (hr)	2012-04-30
HRP20110806T1 (hr)	2011-11-30
CN101801956B (zh)	2013-11-20
BRPI0814428A2 (pt)	2015-01-06
US8178561B2 (en)	2012-05-15
NZ582664A (en)	2012-03-30
US7928230B2 (en)	2011-04-19
JP2010533727A (ja)	2010-10-28
ATE540945T1 (de)	2012-01-15
PE20090449A1 (es)	2009-04-18
DK2170864T3 (da)	2012-01-16
HK1136298A1 (en)	2010-06-25
AU2008276055B2 (en)	2013-01-31
AU2008276057B2 (en)	2013-01-31
WO2009012277A1 (en)	2009-01-22
TW200904439A (en)	2009-02-01
EA018709B1 (ru)	2013-10-30
JP2010533726A (ja)	2010-10-28
ZA201000151B (en)	2011-03-30
EP2170864B1 (en)	2011-09-14
WO2009012275A9 (en)	2010-03-11
BRPI0815097A2 (pt)	2018-07-24

Publication	Publication Date	Title
ZA201000151B (en)	2011-03-30	Pyridone gpr119 g protein-coupled receptor agonists
IL208919A0 (en)	2011-01-31	Gpr119 receptor agonists
EP2173174A4 (en)	2010-08-04	FARNESOID X RECEPTOR AGONISTS
EP2170072A4 (en)	2010-10-27	Farnesoid X RECEPTOR AGONISTS
GB0720390D0 (en)	2007-11-28	G-Protein coupled receptor agonists
GB0720389D0 (en)	2008-11-12	G-Protein Coupled Receptor Agonists
GB0607196D0 (en)	2006-05-17	G-protein coupled receptor agonists
HK1144821A1 (en)	2011-03-11	Glucocorticoid receptor agonists
HRP20151108T1 (en)	2015-11-20	Nogo receptor antagonists
HK1135704A1 (en)	2010-06-11	Piperidine gpcr agonists
HK1135705A1 (en)	2010-06-11	Piperidine gpcr agonists
EP2041120A4 (en)	2010-12-22	MELANOCORTIN RECEPTOR AGONISTS
EP2311822A4 (en)	2011-08-31	GPR119 AGONIST
ZA201103154B (en)	2012-01-25	Melanocortin receptor agonists
EP2184278A4 (en)	2011-08-03	P2X4 RECEIVER ANTAGONIST
IL198650A0 (en)	2010-02-17	Progesterone receptor antagonists
IL212545A0 (en)	2011-06-30	Toll-like receptor 3 antagonists
EP2017281A4 (en)	2012-03-14	AGONISTS AT TOLL-LIKE RECEPTOR 9
EP2153736A4 (en)	2011-08-24	NEW LEUKOTRIEN RECEPTOR ANTAGONIST
ZA201005826B (en)	2011-10-26	Selective agonist of toll-like receptor 3
GB0720388D0 (en)	2007-11-28	G-protein coupled receptor agonists
ZA201103984B (en)	2012-12-27	Toll-like receptor 3 antagonists
GB0701632D0 (en)	2007-03-07	MET receptor antagonists